TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T, Yang Y, Chen Z, Wang J, Wang X, Zheng Y, Wang C, Wang Y, Zhu Z, Ding X, Zhou J, Li G, Zhang H, Zhang W, Wu Y, Song X.
Xu T, et al. Among authors: wang x, wang j, wang y, wang c.
J Exp Clin Cancer Res. 2023 Aug 1;42(1):190. doi: 10.1186/s13046-023-02775-1.
J Exp Clin Cancer Res. 2023.
PMID: 37525222
Free PMC article.